The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.
After reporting a sharp rise in revenues this week, Foundation Medicine discussed changes ahead for the company.
The company plans to bring both tissue-based and blood-based targeted sequencing tests through FDA clearance.
At the Molecular Medicine Tri-Conference, Guardant Health presented details from a 510-patient clinical validation study.
As AstraZeneca takes steps to reintroduce the EGFR-targeted NSCLC drug in the US, Qiagen will develop a tissue-based molecular CDx to accompany the launch.
Cynvenio's LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a blood draw and prepare them for imaging and genomic analysis.
CEO Jay Flatley preannounced fourth-quarter revenues of $512 million and also unveiled the HiSeq X Five System, the HiSeq 3000 and 4000 Systems, and the NextSeq 550 System, an NGS system enabled for array scanning.
The partners hope to detect EGFR mutations in lung cancer patients using Trovagene's Precision Cancer Monitoring platform.
The assay analyzes circulating nucleic acids in blood samples to detect EGFR mutations in non-small cell lung cancer.
Exosome will use the ALCMI samples to support the validation of its ALK and EGFR T790M liquid biopsy tests, which the company plans to launch this year as LDTs.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.